A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a phase II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC.
Epistemonikos ID: d335d93d93e2b44b2907a1b44a36d41acaa3ffb4
First added on: May 08, 2024